FATE
Fate Therapeutics Inc
2.20$
-6.1%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 243.8% | 291.5% | 250.4% | 69.7% | 1,127.2% | 921.5% | 1,788.6% | 200.4% | 1,484.1% | 223.7% | 224.6% | – | – | |
| -143.8% | -191.5% | -150.4% | 30.3% | -1,027.2% | -821.5% | -1,688.6% | -100.4% | -1,384.1% | 100.0% | -124.6% | 100.0% | -343.0% | |
| 1,763.1% | 1,898.3% | 1,669.5% | 511.0% | 1,127.2% | 1,806.9% | 1,788.6% | 1,438.4% | 1,484.1% | 1,857.2% | 1,677.1% | 1,171.3% | 1,501.1% | |
| 974.7% | 1,070.1% | 1,083.4% | 254.7% | 676.7% | 820.5% | 845.5% | 600.2% | 611.0% | 779.0% | 738.7% | 424.1% | 612.0% | |
| 2,494.0% | 2,677.0% | 2,502.4% | 696.0% | 676.7% | 2,498.3% | 845.5% | 1,838.2% | 611.0% | 2,636.2% | 2,415.8% | 1,595.4% | 1,715.1% | |
| -2,637.8% | -2,868.4% | -2,652.9% | -665.7% | -1,703.9% | -3,319.8% | -2,534.1% | -1,938.5% | -1,995.1% | -2,536.2% | -2,540.4% | -1,495.4% | -2,058.1% | |
| – | 579.4% | – | – | – | – | – | – | – | – | – | – | – | |
| -2,323.6% | -2,632.6% | -2,493.7% | -567.4% | -1,551.0% | -2,803.9% | -2,309.5% | -1,786.6% | -1,852.4% | -2,364.8% | -2,402.8% | -1,448.6% | -1,941.1% | |
| -243.8% | 1,123.6% | 248.2% | – | – | -256.9% | – | – | – | – | – | – | – | |
| -2,323.6% | -2,632.6% | -2,493.7% | -567.4% | -1,551.0% | -2,803.9% | -2,309.5% | -1,786.6% | -1,852.4% | -2,364.8% | -2,402.8% | -1,448.6% | -1,941.1% | |
| -2,079.7% | -2,341.1% | -2,243.3% | -497.7% | -1,401.1% | -2,268.7% | -2,104.8% | -1,614.7% | -1,667.0% | -2,141.1% | -2,178.2% | -1,334.0% | -1,762.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.